Skip to main content
FEMY
NASDAQ Industrial Applications And Services

Femasys Unveils Strategic Roadmap for Growth and Revenue Inflection in Women's Health

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.381
Mkt Cap
$23.033M
52W Low
$0.307
52W High
$1.11
52W Position info
24% above low
Off High info
66% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

FEMY sits 24% above its 52-week low of $0.307.

Summary

Femasys Inc. published an investor presentation detailing its strategy for achieving revenue growth and market expansion across its women's health product portfolio, crucial for a company facing going concern issues.


Key Events · Product Development and Regulatory · FEMY

  • Strategic Vision for Women's Health

    The company presented a detailed strategy for its multi-asset portfolio, including FemaSeed for fertility and FemBloc for permanent birth control, targeting large, underserved markets.

  • Path to Revenue Inflection

    The presentation emphasizes "near-term revenue inflection with meaningful growth acceleration" driven by expanding patient access and favorable provider economics.

  • FemaSeed Commercialization

    Highlights FemaSeed's clinical superiority (2X pregnancy rate vs. IUI), compelling economics for OB/GYN practices (potential >$1,000 net revenue per procedure), and upcoming CAT III reimbursement in January 2027.

  • FemBloc Clinical & Market Progress

    Provides updates on the U.S. FINALE pivotal trial enrollment and notes FemBloc's advantages as a non-surgical, hormone-free option with significant profit potential for practices.


Analysis · FEMY · Industrial Applications And Services

Femasys Inc. released a comprehensive investor presentation outlining its strategic vision, product pipeline, and commercialization plans. For a company that recently disclosed "substantial doubt about its ability to continue as a going concern," this detailed roadmap is critical. The presentation highlights significant market opportunities for its fertility (FemaSeed) and permanent birth control (FemBloc) products, emphasizing clinical advantages, favorable economics for healthcare providers, and a clear path to "near-term revenue inflection." It details ongoing clinical trials, regulatory progress, and upcoming commercial milestones through Q4 2026, aiming to instill investor confidence and demonstrate a viable path to financial stability and growth.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, FEMY was trading at $0.38 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $23M. The 52-week trading range was $0.31 to $1.11. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

FEMY - Latest Insights

FEMY
Nov 13, 2026, 4:54 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.44
Real-time Price: $1.24 info
Change: -$0.200 (-14%) info
Market Cap: $10.734M info
FEMY
Sep 29, 2026, 7:02 AM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $2.38
Real-time Price: $1.24 info
Change: -$1.14 (-48%) info
Market Cap: $10.734M info
FEMY
Sep 03, 2026, 5:06 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $3.04
Real-time Price: $1.24 info
Change: -$1.80 (-59%) info
Market Cap: $10.734M info
FEMY
Aug 26, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.88
Real-time Price: $1.24 info
Change: -$1.64 (-57%) info
Market Cap: $10.734M info
FEMY
Aug 19, 2026, 9:02 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $2.15
Real-time Price: $1.24 info
Change: -$0.910 (-42%) info
Market Cap: $10.734M info